

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11396864/publications.pdf>

Version: 2024-02-01

210
papers

28,830
citations

8159

76
h-index

5227

165
g-index

214
all docs

214
docs citations

214
times ranked

32542
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab091.	1.4	6
2	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. <i>Molecular Metabolism</i> , 2022, 61, 101498.	3.0	21
3	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. <i>Npj Breast Cancer</i> , 2021, 7, 18.	2.3	5
4	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 541-550.	0.7	13
5	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. <i>Neoplasia</i> , 2021, 23, 391-399.	2.3	18
6	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.	5.8	24
7	The role of GSK3 in metabolic pathway perturbations in cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119059.	1.9	20
8	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. <i>Carcinogenesis</i> , 2021, 42, 1281-1292.	1.3	5
9	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R83-R103.	1.1	9
10	Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. <i>Breast Cancer Research</i> , 2019, 21, 81.	2.2	10
11	eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5151.	5.8	64
12	Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. <i>Clinical Cancer Research</i> , 2019, 25, 7229-7242.	3.2	26
13	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2019, 111, 970-982.	3.0	43
14	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e323-e328.	0.9	23
15	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF1, IGFII, IGFBP1, IGFBP2 and IGFBP3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	2.3	14
16	mTOR as a central regulator of lifespan and aging. <i>F1000Research</i> , 2019, 8, 998.	0.8	244
17	Serum insulin-like growth factor (IGF)1 and IGF binding protein3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. <i>International Journal of Cancer</i> , 2018, 143, 496-507.	2.3	8
18	Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. <i>Aging Cell</i> , 2018, 17, e12723.	3.0	113

#	ARTICLE	IF	CITATIONS
19	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaptation Pathways to Metformin in Breast Cancer. <i>Cell Metabolism</i> , 2018, 28, 679-688.e4.	7.2	92
20	Translational and HIF-1 α -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018, 28, 817-832.e8.	7.2	61
21	Interplay between ShcA Signaling and PGC-1 α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4826-4838.	0.4	10
22	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	1.3	35
23	Insulin-like growth factor 1 receptor stabilizes the ETV6 α -NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. <i>Journal of Biological Chemistry</i> , 2018, 293, 12502-12515.	1.6	11
24	A phenotype of IGFBP α 3 knockout mice revealed by dextran sulfate α -induced colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 146-153.	1.4	6
25	Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 914-922.	1.1	11
26	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017, 10, 235-243.	0.7	114
27	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1692-1701.	1.8	77
28	The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4541-4547.	1.8	10
29	The effects of metformin on gut microbiota and the immune system as research frontiers. <i>Diabetologia</i> , 2017, 60, 1662-1667.	2.9	79
30	Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 3212-3219.	0.7	7
31	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 267-278.	1.8	14
32	Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. <i>Nutrients</i> , 2017, 9, 378.	1.7	14
33	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. <i>Journal of Clinical Oncology</i> , 2017, 35, 3647-3653.	0.8	40
34	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 50542-50556.	0.8	21
35	Metabolic heterogeneity signature of primary treatment-na α ve prostate cancer. <i>Oncotarget</i> , 2017, 8, 25928-25941.	0.8	16
36	Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. <i>PLoS ONE</i> , 2016, 11, e0167832.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). <i>Oncotarget</i> , 2016, 7, 65643-65659.	0.8	35
38	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1281-1288.	1.1	22
39	Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2016, 26, 11-16.	0.5	6
40	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. <i>Cell Metabolism</i> , 2016, 23, 569-570.	7.2	140
41	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016, 18, 1.	2.2	110
42	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. <i>Breast Cancer Research</i> , 2016, 18, 24.	2.2	18
43	nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. <i>Genome Research</i> , 2016, 26, 636-648.	2.4	177
44	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.4	117
45	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with \sim 4240-Fold Higher Drug Concentration in Urine than Serum. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 430-438.	1.9	16
46	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2283-2289.	3.2	154
47	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. <i>Journal of Clinical Investigation</i> , 2016, 127, 132-136.	3.9	39
48	IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. <i>PLoS ONE</i> , 2016, 11, e0161158.	1.1	39
49	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-7.	0.5	3
50	Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 577-585.	1.1	15
51	mTOR coordinates protein synthesis, mitochondrial activity and proliferation. <i>Cell Cycle</i> , 2015, 14, 473-480.	1.3	397
52	Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. <i>American Journal of Epidemiology</i> , 2015, 182, 187-197.	1.6	50
53	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju085.	3.0	33
54	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	16

#	ARTICLE	IF	CITATIONS
55	Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. <i>Diabetes Care</i> , 2014, 37, 134-143.	4.3	18
56	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. <i>Molecular and Cellular Endocrinology</i> , 2014, 384, 117-125.	1.6	16
57	Serine Deprivation Enhances Antineoplastic Activity of Biguanides. <i>Cancer Research</i> , 2014, 74, 7521-7533.	0.4	113
58	Metformin: From Mechanisms of Action to Therapies. <i>Cell Metabolism</i> , 2014, 20, 953-966.	7.2	1,019
59	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 607-614.	0.6	97
60	Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice. <i>Endocrinology</i> , 2014, 155, 703-715.	1.4	18
61	Metformin directly acts on mitochondria to alter cellular bioenergetics. <i>Cancer & Metabolism</i> , 2014, 2, 12.	2.4	330
62	Serum transforming growth factor- β 1 and risk of pancreatic cancer in three prospective cohort studies. <i>Cancer Causes and Control</i> , 2014, 25, 1083-1091.	0.8	12
63	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. <i>Nature Medicine</i> , 2014, 20, 591-593.	15.2	95
64	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). <i>European Urology</i> , 2014, 66, 468-474.	0.9	100
65	Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. <i>Growth Hormone and IGF Research</i> , 2014, 24, 142-149.	0.5	3
66	Metformin improves healthspan and lifespan in mice. <i>Nature Communications</i> , 2013, 4, 2192.	5.8	1,118
67	mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. <i>Cell Metabolism</i> , 2013, 18, 698-711.	7.2	647
68	Exercise Does Not Counteract the Effects of a "Westernized" Diet on Prostate Cancer Xenografts. <i>Prostate</i> , 2013, 73, 1223-1232.	1.2	8
69	Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. <i>Carcinogenesis</i> , 2013, 34, 109-112.	1.3	42
70	Targeting Oxidative Phosphorylation: Why, When, and How. <i>Cancer Cell</i> , 2013, 23, 263-264.	7.7	47
71	IGF2 increases de novo steroidogenesis in prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 173-186.	1.6	48
72	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	13.5	348

#	ARTICLE	IF	CITATIONS
73	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. <i>Genes and Cancer</i> , 2013, 4, 535-545.	0.6	3
74	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	3.0	80
75	Insulin-Like Growth Factors and Insulin-Like Growth Factor-1 Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2013, 6, 91-99.	0.7	28
76	Potential applications for biguanides in oncology. <i>Journal of Clinical Investigation</i> , 2013, 123, 3693-3700.	3.9	162
77	Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. <i>PLoS ONE</i> , 2013, 8, e79710.	1.1	29
78	Metformin, aging and cancer. <i>Aging</i> , 2013, 5, 330-331.	1.4	41
79	Metformin and Hepatic Carcinogenesis. <i>Cancer Prevention Research</i> , 2012, 5, 500-502.	0.7	9
80	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3407-3413.	3.2	47
81	The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology. <i>Clinical Cancer Research</i> , 2012, 18, 40-50.	3.2	89
82	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-11.	0.6	24
83	Metformin and Pancreatic Cancer: A Clue Requiring Investigation. <i>Clinical Cancer Research</i> , 2012, 18, 2723-2725.	3.2	31
84	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. <i>Blood</i> , 2012, 120, 4929-4937.	0.6	41
85	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. <i>Cancer Causes and Control</i> , 2012, 23, 779-784.	0.8	18
86	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. <i>Experimental Hematology</i> , 2012, 40, 715-723.e6.	0.2	20
87	Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women. <i>Diabetes</i> , 2012, 61, 2248-2254.	0.3	116
88	IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors. <i>Science Signaling</i> , 2012, 5, ra92.	1.6	123
89	Distinct perturbation of the transcriptome by the antidiabetic drug metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8977-8982.	3.3	169
90	Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. <i>International Journal of Cancer</i> , 2012, 131, E105-13.	2.3	51

#	ARTICLE	IF	CITATIONS
91	Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. <i>Endocrine-Related Cancer</i> , 2012, 19, 557-574.	1.6	10
92	A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. <i>Cancer Causes and Control</i> , 2012, 23, 959-965.	0.8	35
93	The insulin and insulin-like growth factor receptor family in neoplasia: an update. <i>Nature Reviews Cancer</i> , 2012, 12, 159-169.	12.8	929
94	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 131-142.	1.1	117
95	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 694-699.	1.0	80
96	A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. <i>Cancer Causes and Control</i> , 2011, 22, 1627-1637.	0.8	46
97	Human prostate cancer xenografts in <i>lit/lit</i> mice exhibit reduced growth and androgen-independent progression. <i>Prostate</i> , 2011, 71, 525-537.	1.2	19
98	Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 337-344.	1.1	120
99	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2618-2627.	1.1	50
100	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Experimental Medicine</i> , 2011, 208, 1809-1822.	4.2	153
101	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011, 29, 3605-3610.	0.8	57
102	Metformin abolishes increased tumor 18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. <i>Cell Cycle</i> , 2011, 10, 2770-2778.	1.3	38
103	ETV6-NTRK3-Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway. <i>Cancer Research</i> , 2011, 71, 1060-1070.	0.4	61
104	IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, 699-709.	1.6	31
105	Insulin Increases <i>De Novo</i> Steroidogenesis in Prostate Cancer Cells. <i>Cancer Research</i> , 2011, 71, 5754-5764.	0.4	97
106	Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose. <i>Journal of Biological Chemistry</i> , 2011, 286, 16567-16573.	1.6	10
107	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Cell Biology</i> , 2011, 194, i8-i8.	2.3	0
108	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 647-659.	1.1	37

#	ARTICLE	IF	CITATIONS
109	Diabetes and Cancer: A Consensus Report. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 207-221.	157.7	724
110	A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. <i>Prostate</i> , 2010, 70, 848-855.	1.2	141
111	Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. <i>Prostate</i> , 2010, 70, 1628-1635.	1.2	23
112	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14134-14139.	3.3	447
113	Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2010, 3, 279-289.	0.7	33
114	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. <i>Human Molecular Genetics</i> , 2010, 19, 3873-3884.	1.4	45
115	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. <i>Endocrine-Related Cancer</i> , 2010, 17, 351-360.	1.6	203
116	Diabetes and Cancer. <i>Diabetes Care</i> , 2010, 33, 1674-1685.	4.3	1,618
117	IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. <i>Growth Factors</i> , 2010, 28, 243-255.	0.5	46
118	Effect of Isocaloric Low Fat Diet on Prostate Cancer Xenograft Progression in a Hormone Deprivation Model. <i>Journal of Urology</i> , 2010, 183, 1619-1624.	0.2	14
119	Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. <i>Cancer Prevention Research</i> , 2010, 3, 1060-1065.	0.7	205
120	Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. <i>Cancer Letters</i> , 2010, 289, 246-253.	3.2	27
121	Protective effect of metformin in CD1 mice placed on a high carbohydrate "high fat diet. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 537-542.	1.0	40
122	Beyond steroid hormones: the new cancer endocrinology. <i>Lancet Oncology</i> , The, 2010, 11, 501-502.	5.1	1
123	The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model. <i>Cancer Prevention Research</i> , 2009, 2, 557-565.	0.7	98
124	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. <i>Cancer Research</i> , 2009, 69, 2443-2452.	0.4	96
125	Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care?. <i>Cancer Prevention Research</i> , 2009, 2, 698-701.	0.7	6
126	Insulin receptor expression by human prostate cancers. <i>Prostate</i> , 2009, 69, 33-40.	1.2	203

#	ARTICLE	IF	CITATIONS
127	Aging, IGF-1, and diet. <i>Aging Cell</i> , 2009, 8, 214-214.	3.0	1
128	Do Cancer Cells Care If Their Host Is Hungry?. <i>Cell Metabolism</i> , 2009, 9, 401-403.	7.2	34
129	Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 634-640.	2.2	214
130	Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy. <i>BioDrugs</i> , 2009, 23, 77-91.	2.2	45
131	Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. <i>Current Drug Targets</i> , 2009, 10, 923-936.	1.0	55
132	Energy Metabolism, Cancer Risk, and Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2009, 181, 51-54.	1.8	8
133	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008, 68, 1477-1486.	1.2	54
134	Insulin and insulin-like growth factor signalling in neoplasia. <i>Nature Reviews Cancer</i> , 2008, 8, 915-928.	12.8	1,792
135	Insulin, insulin-like growth factors and neoplasia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 625-638.	2.2	85
136	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. <i>Breast Cancer Research</i> , 2008, 10, R86.	2.2	107
137	Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. <i>Breast Cancer Research</i> , 2008, 10, R42.	2.2	12
138	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. <i>Growth Hormone and IGF Research</i> , 2008, 18, 166-173.	0.5	65
139	Targeting insulin and insulin-like growth factor signalling in oncology. <i>Current Opinion in Pharmacology</i> , 2008, 8, 384-392.	1.7	90
140	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. <i>Lancet Oncology</i> , The, 2008, 9, 1039-1047.	5.1	385
141	Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival. <i>Cancer Research</i> , 2008, 68, 10238-10246.	0.4	364
142	Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers. <i>American Journal of Epidemiology</i> , 2008, 168, 1047-1055.	1.6	70
143	The Type 1 Insulin-Like Growth Factor Receptor Pathway. <i>Clinical Cancer Research</i> , 2008, 14, 6364-6370.	3.2	387
144	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. <i>Endocrine-Related Cancer</i> , 2008, 15, 833-839.	1.6	165

#	ARTICLE	IF	CITATIONS
145	Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 880-888.	1.1	58
146	Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study. <i>Clinical Chemistry</i> , 2008, 54, 1682-1688.	1.5	21
147	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6944-6954.	3.2	71
148	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	3.2	52
149	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	0.8	152
150	IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). <i>PLoS ONE</i> , 2008, 3, e2578.	1.1	106
151	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	2.0	263
152	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1793-1800.	3.0	160
153	Synchronized Seasonal Variations of Mammographic Breast Density and Plasma 25-Hydroxyvitamin D. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 929-933.	1.1	49
154	Metformin Inhibits Mammalian Target of Rapamycin-Dependent Translation Initiation in Breast Cancer Cells. <i>Cancer Research</i> , 2007, 67, 10804-10812.	0.4	845
155	The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. <i>Cancer Letters</i> , 2007, 255, 300-306.	3.2	29
156	Hypoxia-inducible factor-1 (HIF-1) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. <i>Prostate</i> , 2007, 67, 1354-1361.	1.2	49
157	Insulin-Like Growth Factor-Related Signaling and Cancer Development. , 2007, 174, 49-53.		54
158	Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 10269-10273.	0.4	972
159	Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 1518-1526.	2.2	21
160	Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006, 118, 1279-1284.	2.3	32
161	Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. <i>Cancer Research</i> , 2006, 66, 588-597.	0.4	55
162	Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. <i>Molecular Pharmacology</i> , 2006, 70, 1534-1541.	1.0	74

#	ARTICLE	IF	CITATIONS
163	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. <i>Oncogene</i> , 2005, 24, 4736-4740.	2.6	58
164	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. <i>Oncogene</i> , 2005, 24, 4281-4292.	2.6	251
165	Individualizing Interventions for Cancer Prevention. , 2005, 166, 63-70.		0
166	Levels of C-Peptide and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2661-2664.	1.1	17
167	Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1653-1659.	1.1	91
168	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1402-1410.	1.1	18
169	Serum Insulin-Like Growth Factor-I Levels and Prostatic Intraepithelial Neoplasia: A Clue to the Relationship Between IGF-I Physiology and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1270-1273.	1.1	28
170	Insulin-Like Growth Factor-I, IGF-Binding Protein-3, and Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1065-1073.	1.1	134
171	PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1056-1061.	1.0	51
172	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. <i>Breast Cancer Research</i> , 2005, 7, R796-807.	2.2	83
173	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. <i>Breast Cancer Research</i> , 2005, 7, R570-9.	2.2	112
174	A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men. <i>Journal of the National Cancer Institute</i> , 2004, 96, 546-553.	3.0	311
175	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. <i>International Journal of Cancer</i> , 2004, 108, 334-341.	2.3	193
176	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. <i>International Journal of Cancer</i> , 2004, 108, 773-779.	2.3	81
177	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shcâ€‘MAPK signaling pathway in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 313, 709-715.	1.0	30
178	Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 421-428.	1.0	30
179	Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 438-44.	1.1	22
180	Mammary-specific deletion of parathyroid hormoneâ€‘related protein preserves bone mass during lactation. <i>Journal of Clinical Investigation</i> , 2003, 112, 1429-1436.	3.9	156

#	ARTICLE	IF	CITATIONS
181	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 84-9.	1.1	112
182	Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. <i>Cancer Research</i> , 2003, 63, 3991-4.	0.4	94
183	Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1099-1106.	3.0	377
184	Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2002, 168, 2426-2430.	0.2	22
185	Risk of cancer after growth-hormone treatment. <i>Lancet, The</i> , 2002, 360, 268-269.	6.3	18
186	Reduced growth of human sarcoma xenografts in hosts homozygous for the IGF1 mutation. <i>Journal of Surgical Oncology</i> , 2002, 81, 75-79.	0.8	29
187	Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. <i>Cancer Research</i> , 2002, 62, 7372-6.	0.4	33
188	Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. <i>Medical Science Monitor</i> , 2002, 8, BR521-6.	0.5	71
189	Genetic Factors Related to Racial Variation in Plasma Levels of Insulin-Like Growth Factor-1: Implications for Premenopausal Breast Cancer Risk. <i>Molecular Genetics and Metabolism</i> , 2001, 72, 144-154.	0.5	101
190	Other novel agents: Rationale and current status as chemopreventive agents. <i>Urology</i> , 2001, 57, 86-89.	0.5	14
191	Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). <i>Journal of the National Cancer Institute</i> , 2001, 93, 1852-1857.	3.0	815
192	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1274-1280.	1.8	178
193	Insulin-like growth factor physiology and neoplasia. <i>Growth Hormone and IGF Research</i> , 2000, 10, S6-S7.	0.5	21
194	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2000, 10, S32-S33.	0.5	39
195	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. <i>Molecular and Cellular Biochemistry</i> , 1999, 199, 41-48.	1.4	18
196	Circulating IGF-I: New Perspectives for a New Century. <i>Trends in Endocrinology and Metabolism</i> , 1999, 10, 136-141.	3.1	128
197	Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. <i>Urology</i> , 1999, 54, 1120-1125.	0.5	39
198	Insulin-like growth factors and prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1998, 17, 383-390.	2.7	142

#	ARTICLE	IF	CITATIONS
199	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. , 1998, 69, 21-27.		94
200	Insulin-like growth factor-I and risk of breast cancer. Lancet, The, 1998, 352, 489.	6.3	3
201	Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet, The, 1998, 351, 1393-1396.	6.3	1,706
202	Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science, 1998, 279, 563-566.	6.0	1,872
203	Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. Endocrinology, 1998, 139, 807-810.	1.4	110
204	Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 1997, 237, 690-693.	1.0	145
205	Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells. Journal of Biological Chemistry, 1996, 271, 1016-1021.	1.6	190
206	HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI). In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 25-29.	0.7	23
207	Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: Correlations with effects on proliferation: A review. Progress in Growth Factor Research, 1995, 6, 495-501.	1.7	12
208	The insulinâ€“insulin-like growth-factor receptor family as a therapeutic target in oncology. , 0, , 110-118.		0
209	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles. , 0, .		13
210	Translational and HIF11-Dependent Metabolic Reprograming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides. SSRN Electronic Journal, 0, , .	0.4	1